CD20 expression in Hodgkin and Reed-Sternberg cells of classical Hodgkin's disease: Associations with presenting features and clinical outcome

Journal of Clinical Oncology

Volumn 20, Issue 5, 2002, Pages 1278-1287

  Rassidakis, George Z ^a   Medeiros, L Jeffrey ^a   Viviani, Simonetta ^a   Bonfante, Valeria ^a   Nadali, Gian Paolo ^a   Vassilakopoulos, Theodoros P ^a   Mesina, Ofelia ^a   Herling, Marco ^a   Angelopoulou, Maria K ^a   Giardini, Roberto ^a   Chilosi, Marco ^a   Kittas, Christos ^a   McLaughlin, Peter ^a   Rodriguez, M Alma ^a   Romaguera, Jorge ^a   Bonadonna, Gianni ^a   Gianni, Alessandro M ^a   Pizzolo, Giovanni ^a   Pangalis, Gerassimos A ^a   Cabanillas, Fernando ^a   Sarris, Andreas H ^a   more..

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BLEOMYCIN; CARMUSTINE; CD20 ANTIGEN; CHLORMETHINE; CYCLOPHOSPHAMIDE; DACARBAZINE; DOXORUBICIN; EPIRUBICIN; ETOPOSIDE; MITOXANTRONE; PREDNISONE; PROCARBAZINE; VINBLASTINE; VINCRISTINE;

ANTIGEN EXPRESSION; ARTICLE; CANCER REGRESSION; CANCER STAGING; CANCER SURVIVAL; CLINICAL FEATURE; GERMINAL CENTER; HODGKIN DISEASE; IMMUNOHISTOCHEMISTRY; LYMPH NODE BIOPSY; OUTCOMES RESEARCH; PRIORITY JOURNAL; REED STERNBERG CELL;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTIGENS, CD20; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BLEOMYCIN; CHILD; COMBINED MODALITY THERAPY; DACARBAZINE; DOXORUBICIN; FEMALE; HODGKIN DISEASE; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MIDDLE AGED; NEOPLASM STAGING; PREDNISONE; REED-STERNBERG CELLS; SURVIVAL RATE; VINBLASTINE;

EID: 0036498728     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.20.5.1278     Document Type: Article

References (53)

1. Twenty years of MOPP therapy for Hodgkin's disease
2. Hodgkin's disease
3. Chemotherapy of advanced Hodgkin's disease with MOPP, ABVD, or MOPP alternating with ABVD
4. Prognostic factors among 185 adults with newly diagnosed advanced Hodgkin's disease treated with alternating potentially noncross-resistant chemotherapy and intermediate-dose radiation therapy
5. A numerical prognostic index for clinical use in identification of poor-risk patients with Hodgkin's disease at diagnosis: The Scotland and Newcastle Lymphoma Group (SNLG) Therapy Working Party
6. Prognostic factors in advanced Hodgkin's disease: Problems and pitfalls. Towards an international prognostic index
7. Advanced Hodgkin's disease: Validation of the MSKCC prognostic model. How to identify a high-risk group qualifying for intensive initial treatment? The GELA study
8. A prognostic model for advanced Hodgkin's Disease at M.D. Anderson validated with an independent set of patients treated at Memorial Sloan-Kettering
9. A prognostic model for failure-free survival (FFS) of adults with clinical Ann Arbor stage (AAS) I/II Hodgkin's disease (HD) after combined modality therapy
10. A predictive model for failure-free survival (FFS) of adults with Hodgkin's disease treated with ABVD or equivalent regimens
11. A prognostic score for advanced Hodgkin's disease
12. Interleukin-10 levels are often elevated in serum of adults with Hodgkin's disease and are associated with inferior failure-free survival
13. Elevated pretreatment serum levels of II-10 are associated with a poor prognosis in Hodgkin's Disease: The Milan Cancer Institute experience
14. Poor clinical outcome of patients with Hodgkin's disease and elevated interleukin-10 serum levels: Clinical significance of interleukin-10 serum levels for Hodgkin's disease
15. Serum interleukin-10 levels are an independent prognostic factor for patients with Hodgkin's lymphoma
16. The origin of Hodgkin and Reed/Sternberg cells in Hodgkin's disease
17. Origin of nodular lymphocyte-predominant Hodgkin's disease from a clonal expansion of highly mutated germinal-center B cells
18. Clonality in nodular lymphocyte-predominant Hodgkin's disease
19. Hodgkin's disease with monoclonal and polyclonal populations of Reed-Sternberg cells
20. Hodgkin's disease, lymphocyte predominance type, nodular: Further evidence for a B cell derivation. L & H variants of Reed-Sternberg cells express L26, a pan B cell marker
21. Expression of B-cell antigens by Hodgkin's and Reed-Sternberg cells
22. Coexpression of CD15 and CD20 by Reed-Sternberg cells in Hodgkin's disease
23. Inconsistency of the immunophenotype of Reed-Sternberg cells in simultaneous and consecutive specimens from the same patients: A paraffin section evaluation in 56 patients
24. Immunohistochemical characteristics of Hodgkin and Reed-Sternberg cells in relation to age and clinical outcome
25. Decreased expression of cellular markers in Epstein-Barr virus-positive Hodgkin's disease
26. Immunophenotype of Reed-Sternberg and Hodgkin's cells in sequential biopsy specimens of Hodgkin's disease: A paraffin-section immunohistochemical study using the heat-induced epitope retrieval method
27. Classical Hodgkin's disease: Clinical impact of the immunophenotype
28. The expression of the B-cell marker mb-1 (CD79a) in Hodgkin's disease
29. Frequent expression of the B-cell-specific activator protein in Reed-Sternberg cells of classical Hodgkin's disease provides further evidence for its B-cell origin
30. Transcription factor B-cell-specific activator protein (BSAP) is differentially expressed in B cells and in subsets of B-cell lymphomas
31. Molecular cloning of the human B cell CD20 receptor predicts a hydrophobic protein with multiple transmembrane domains
32. Structure of the gene encoding the human B lymphocyte differentiation antigen CD20 (BI)
33. CD20: A regulator of cell-cycle progression of B lymphocytes
34. Lymphocytepredominant Hodgkin's disease: An immunohistochemical analysis of 208 reviewed Hodgkin's disease cases from the German Hodgkin Study Group
35. European Task Force on Lymphoma project on lymphocyte predominance Hodgkin disease: Histologic and immunohistologic analysis of submitted cases reveals 2 types of Hodgkin disease with a nodular growth pattern and abundant lymphocytes
36. Pathology of classical Hodgkin's disease
37. IDEC-C2B8 (rituximab) anti-CD20 monoclonal antibody therapy in patients with relapsed low-grade non-Hodgkin's lymphoma
38. Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: Half of patients respond to a four-dose treatment program
39. Rituximab (anti-CD20 monoclonal antibody) as single first-line therapy for patients with follicular lymphoma with a low tumor burden: Clinical and molecular evaluation
40. Mabthera (rituximab) plus CHOP is superior to CHOP alone in elderly patients with diffuse large B-cell lymphoma (DLCL): Interim results of a randomized GELA trial
41. Rituximab is active in lymphocyte predominance Hodgkin's disease
42. Increased treatment failure in patients with CD20 positive classic Hodgkin's disease (HD)
43. A revised European American classification of lymphoid neoplasms: A proposal from the International Lymphoma Study Group
44. Classical Hodgkin lymphoma
45. Report of the committee on Hodgkin's disease staging classification
46. Alternating non-cross-resistant combination chemotherapy or MOPP in stage IV Hodgkin's disease: A report of 8-year results
47. EBVD combination chemotherapy plus low dose involved field radiation is a highly effective treatment modality for early stage Hodgkin's disease
48. NOVP and radiotherapy for early-staged Hodgkin's disease: An interim analysis
49. Long-term results of an intensive regimen: VEBEP plus involved-field radiotherapy in advanced Hodgkin's disease
50. Differential expression of BCL-2 family proteins in ALK-positive and ALK-negative anaplastic large cell lymphoma of T/null-cell lineage
51. Non-parametric estimation from incomplete observations
52. Evaluation of survival data and two new rank order statistics arising in its consideration
53. The B cell-specific transcription factor BSAP regulates B cell proliferation